<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434548</url>
  </required_header>
  <id_info>
    <org_study_id>HD123</org_study_id>
    <nct_id>NCT03434548</nct_id>
  </id_info>
  <brief_title>Huntington's Disease 123</brief_title>
  <official_title>Huntington's Disease 123</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the program is to derive biomarkers that could be further developed to
      measure the efficacy of novel pharmacological treatments for HD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in binding profile of four discrete molecular PET markers</measure>
    <time_frame>From study enrolment up to 24 months</time_frame>
    <description>Determine whether selected PET markers could be used as markers of HD disease progression and treatment response in therapeutic trials.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Healthy Controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Huntington's Disease Gene Expansion Carriers (HDGECs: premanifest near-onset, peri-manifest, and manifest), and Healthy Controls</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Analysis will be performed to confirm the size of the CAG expansion mutation within the HD
      gene for all HDGEC participants, for research purposes only.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls (HCs) and Huntington's Disease Gene Expansion Carriers (HDGECs).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be capable of giving informed consent

          -  Must be willing to comply with adequate contraceptive measures

          -  Must be considered by the Investigator to be in good heath (excluding disease under
             study)

        Exclusion Criteria:

          -  Individuals who do not meet inclusion criteria

          -  Known intracranial comorbidities (i.e. stroke, haemorrhage, space-occupying lesions
             etc.)

          -  The presence or history of other neurological or primary psychiatric disorders
             secondary to HD

          -  Pregnancy

          -  Breastfeeding

          -  Contraindication to MRI (e.g. presence of metal devices, metal deposited in the body)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chloe Farrell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chloe Farrell, PhD</last_name>
    <phone>00442078485452</phone>
    <email>chloe.farrell@kcl.ac.uk</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

